I have been on an aromatase inhibitor for the past eight months and have side effects that keep me from having a good quality of life. I am supposed to be on it for five years, but I do not want to ...
Cognitive dysfunction has been considered as a morbid condition that may possibly result from aromatase inhibitor therapy, the standard treatment in postmenopausal, estrogen/progesterone receptor ...
Findings from the NATALEE trial show that the combination of Kisqali and an aromatase inhibitor resulted in disease-free benefits in a breast cancer subset. For patients with hormone receptor ...
New evidence shows that extended estrogen suppression treatment using aromatase inhibitors for hormone receptor-positive postmenopausal breast cancer is safe; it does not increase the risk of ...
Kisqali has been FDA-approved with an aromatase inhibitor as postsurgical treatment for some with early breast cancer at a high risk of recurrence. The Food and Drug Administration (FDA) has approved ...
The drug joins abemaciclib (Verzenio ... 3 years of adjuvant treatment with ribociclib plus a non-steroidal aromatase inhibitor reduced the risk of disease recurrence by 25% versus an aromatase ...
Basel, September 17, 2024 – Novartis today announced that the US Food and Drug Administration (FDA) has approved Kisqali ® (ribociclib) in combination with an aromatase inhibitor (AI ...
The FDA approved ribociclib (Kisqali) for adjuvant treatment of high-risk, hormone receptor-positive, HER2-negative early breast cancer. The FDA approved ribociclib (Kisqali) with an aromatase ...
Ability To Add Other Drugs With RLY-2608 Doublet To Go Beyond ... was approved back in 2017 with an aromatase inhibitor [AI] or fulvestrant to treat pre/perimenopausal or postmenopausal women ...